Kropf, Jacqueline Cheyney, Sarah Vachon, Josselin Flaherty, Philip Vo, Mai Carlan, Steve J.
Published in
Clinics and Practice
Catastrophic thrombotic syndrome, otherwise known as thrombotic storm (TS) is an extreme prothrombotic clinical syndrome that presents as rapid onset of multiple thromboembolic events affecting a large variety of vasculature. In recent studies, there has been a correlation of high plasma levels of factor VIII with thrombotic events. We present the ...
Schütte, Lisette M Hodes, Luca S van Moort, Iris Stoof, Sara C M Leebeek, Frank W G Cnossen, Marjon H de Maat, Moniek P M Kruip, Marieke J H A
Published in
Haemophilia : the official journal of the World Federation of Hemophilia
Diagnosis, treatment monitoring and assessment of desmopressin effect in haemophilia A patients are performed by measurement of factor VIII activity (FVIII). The two assays commonly applied are the one-stage assay and the chromogenic assay. Especially in non-severe haemophilia A, discrepancies between these assays are common. It is still unestablis...
Karch, Corinne Masser-Frye, Diane Limjoco, Jacqueline Ryan, Sarah E Fletcher, Shelley N Corbett, Kevin D Johnsen, Jill M Thornburg, Courtney D
We report 2 patients with coinheritance of the X-linked bleeding disorders hemophilia A and hemophilia B. We describe the family pedigrees, clinical features, and genotyping. The case report addresses the key clinical questions of how to manage patients with both hemophilia A and B and how to counsel families regarding recurrence risk. The patients...
Cai, Yuanhua Shi, Qizhen
Published in
Frontiers in Immunology
Platelets are small anucleated blood components primarily described as playing a fundamental role in hemostasis and thrombosis. Over the last decades, increasing evidence has demonstrated the role of platelets in modulating inflammatory reactions and immune responses. Platelets harbor several specialized organelles: granules, endosomes, lysosomes, ...
Bowyer, Annette E Lowe, Anna E Tiefenbacher, Stefan
Published in
Haemophilia : the official journal of the World Federation of Hemophilia
The treatment options for the haemostatic disorders, haemophilia A and haemophilia B, have progressed rapidly over the last decade. The introduction of extended half-life recombinant factor VIII (FVIII) and factor IX (FIX) concentrates to replace these missing clotting factors highlighted discordance between one-stage activated partial thromboplast...
Ling, Gavin Tuddenham, Edward G D
Published in
British journal of haematology
The foundation of haemophilia A therapy in the last 35 years has been critically dependent on isolation of the Factor VIII (FVIII) protein and discovery of the cDNA sequence of the FVIII gene, published in 1984. Identification of the FVIII sequence resulted in a new era of recombinant concentrates and led to significant improvements in safety, set ...
Chen, Alex C. Cai, Xiaohe Li, Chong Khoryati, Liliane Gavin, Marc A. Miao, Carol H.
Published in
Frontiers in Immunology
Hemophilia A is a genetic disorder that results in the deficiency of functional factor VIII protein, which plays a key role in blood coagulation. Currently, the majority of hemophilia A patients are treated with repeated infusions of factor VIII protein. Approximately 30% of severe hemophilia A patients develop neutralizing antibodies to factor VII...
Allard, Quentin Djerada, Zoubir Pouplard, Claire Repessé, Yohann Desprez, Dominique Galinat, Hubert Frotscher, Birgit Berger, Claire Harroche, Annie Ryman, Anne
...
Published in
Pharmaceutics
We retrospectively analysed the data files of 171 adults and 87 children/adolescents with severe haemophilia, except for 14 patients (moderate; minor) (1), to develop a global population pharmacokinetic (PK) model for eight factors VIII (FVIII) that could estimate individual PK parameters for targeting the desired level of FVIII activity (FVIII:C);...
Chen, Chun-Yu Tran, Dominic M. Cavedon, Alex Cai, Xiaohe Rajendran, Raj Lyle, Meghan J. Martini, Paolo G.V. Miao, Carol H.
Published in
Molecular Therapy. Nucleic Acids
Messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) can be efficiently delivered into the liver. LNPs carrying FVIII mRNA (F8 LNPs) produced rapid and prolonged duration of FVIII expression in hemophilia A mice. This safe and effective platform of new mRNA therapies could be used for prophylactic treatment and potentially various other ...
Cormier, Matthew Batty, Paul Tarrant, Julie Lillicrap, David
Published in
British journal of haematology
Anti-drug antibody formation following factor VIII (FVIII) replacement therapy is the most important treatment-related complication in patients with severe haemophilia A. A significant number of these antibodies show neutralising activity against FVIII and are referred to as FVIII inhibitors. Alloimmunity to FVIII, given the absence of endogenous c...